← All trials
NCT04596878
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 19, 2020
- Primary completion
- Jun 30, 2021
- Completion date
- Jun 30, 2022
- First posted
- Oct 22, 2020
- Last posted
- Dec 11, 2020
- Enrollment
- 150
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Minervax ApSLead sponsor
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
- University of LondonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.